

# Accelerating Innovation to Improve Patients' Lives

Navika Bio bridges East and West, connecting groundbreaking Asian biotech innovation with global pharmaceutical partners to deliver transformative therapies to patients worldwide.



# Bridging Portfolio Gaps in BioPharma

Leading pharmaceutical manufacturers face unprecedented challenges as blockbuster drugs lose exclusivity and new therapeutic modalities reshape competitive dynamics. Tomorrow's winners will be defined not by internal R&D prowess alone, but by their agility in accessing and integrating external innovation.



## Strategic Partnership Opportunities

Priority Focus Area	Strategic Rationale	Example Deal Types
Bolster Novel Modalities	Acquire transformative platforms and next-generation capabilities	Acquisitions of biotechs with cell/gene therapy and RNA platforms
Diversify Therapeutic Pipelines	Mitigate concentration risk and access new high-growth therapeutic vectors	Licensing Phase II/III assets in Neurology and Cardiometabolic diseases
Secure "Pipeline-in-a-Product"	Identify assets with multi-indication potential and platform scalability	Strategic alliances on mid-stage assets with broad therapeutic applications

# How Navika Bio Adds Value

Navika Bio has nurtured relationships with Asian biotechnology leaders and has identified over 20 licensable drug candidates across **Oncology**, **Autoimmune Diseases**, and **Weight Loss**. This curated pipeline continues to expand as we deepen our networks and scientific expertise.

01

---

## Scout & Select

Asia's biotechnology sector is experiencing explosive growth, driven by government policy support, direct investment, and reverse brain drain. While these innovations were previously inaccessible to Western investors, funding gaps have created strategic entry points for partnerships.

03

---

## Curate & Accelerate

Navika Bio adds value beyond asset identification and rights negotiation. We leverage our scientific, regulatory, and commercial expertise to expedite development timelines, de-risk drug candidates, and facilitate successful business development transactions.

02

---

## Screen & In-License

Many pharmaceutical companies are actively scouting Asian biotech, but lack the scale, local presence and trusted connections to identify the most compelling opportunities. Navika Bio understands their pipeline gaps and is uniquely positioned to identify, screen, and secure attractive assets from proven bioinnovation centers.

04

---

## Out-License & Reinvest

We aim to out-license or divest assets to established biopharmaceutical companies seeking to strengthen their pipelines. Proceeds from successful transactions are strategically reinvested into new high-potential clinical opportunities, creating a sustainable cycle of innovation.

# Navika Bio's Advantage: Bridging Biotech

Navika Bio's distinct capabilities ensure successful partnerships and accelerated delivery of groundbreaking therapies to patients worldwide.



## Unmatched Network

Extensive relationships with leading biotech innovators in Asia and key pharmaceutical players globally.



## Deep Scientific Expertise

Rigorous scientific and clinical evaluation to identify and de-risk the most promising drug candidates.



## Market Insight

In-depth understanding of regulatory landscapes and commercial potential in both Eastern and Western markets.



## Expedited Development Path

A proven framework to accelerate drug development, from scouting to out-licensing and reinvestment.

# Let's Connect

For more information about partnership opportunities and to join us on this exciting journey of bringing transformative therapies to patients worldwide, please reach out to:



**Richard Cunningham, MBA CMA**

**Phone:** 203-212-0949

**Email:** [richard@navikabio.com](mailto:richard@navikabio.com)

